Cormorant Asset Management has significantly increased its stake in MoonLake Immunotherapeutics, acquiring 2,361,260 shares valued at approximately $27.86 million, as disclosed in a February 17, 2026 SEC filing. This move raises Cormorant’s holdings in MoonLake to 2.65% of its reportable U.S. equities, reflecting a strategic bet on the biotech firm despite its recent struggles.

The investment comes on the heels of a dramatic nearly 90% stock drop for MoonLake following disappointing Phase 3 trial results for its lead drug, sonelokimab. However, early clinical data has shown promise, and recent trial results may indicate potential for new indications in the growing immunology market. With the company’s fourth-quarter R&D expenses at $56 million and a cash reserve of $394 million, it appears well-positioned to navigate its clinical trials.

For investors, Cormorant’s purchase suggests confidence in MoonLake’s long-term prospects, potentially marking an attractive entry point amid its recent volatility. For a deeper dive into this development, I recommend checking out the full article.

Source: fool.com